Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPS

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19), Zacks reports.

Lexeo Therapeutics Trading Down 10.3%

Lexeo Therapeutics stock opened at $2.69 on Monday. The company has a market capitalization of $89.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.27. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $19.50. The business's fifty day simple moving average is $3.06 and its two-hundred day simple moving average is $5.14.

Wall Street Analyst Weigh In

A number of equities analysts have commented on LXEO shares. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Finally, Chardan Capital decreased their price target on Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $22.20.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.